{"id":"five-days-oseltamivir-baloxavir-marboxil","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir is a neuraminidase inhibitor that prevents viral release from infected cells by blocking sialic acid cleavage. Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks viral mRNA synthesis at an earlier stage. The combination approach aims to reduce treatment duration while maintaining efficacy and potentially reducing resistance development through dual-mechanism targeting.","oneSentence":"This combination uses two antiviral agents with different mechanisms to inhibit influenza virus replication through dual targeting of viral neuraminidase and cap-dependent endonuclease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:39.268Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute uncomplicated influenza in adults and adolescents (treatment)"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Five-days oseltamivir + baloxavir marboxil","genericName":"Five-days oseltamivir + baloxavir marboxil","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses two antiviral agents with different mechanisms to inhibit influenza virus replication through dual targeting of viral neuraminidase and cap-dependent endonuclease. Used for Acute uncomplicated influenza in adults and adolescents (treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}